- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942168
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma (SARCOGYN)
Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment
The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alexander Anokhin, PhD
- Phone Number: +7-915-518-85-00
- Email: anokhinaleks@mail.ru
Study Locations
-
-
-
Moscow, Russia
- Recruiting
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
-
Contact:
- Alexander Anokhin, PhD
- Phone Number: +7-915-518-85-00
- Email: anokhinaleks@mail.ru
-
Contact:
- Alexey Rumyantsev, PhD
- Phone Number: +7-499-324-10-87
- Email: a.rumyantsev@ronc.ru
-
Principal Investigator:
- Alexander Anokhin, PhD
-
Sub-Investigator:
- Alexey Rumyantsev, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Morphologically verified uterine leiomyosarcoma
- Age 18 to 70 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
- No prior systemic anticancer therapy
- No contraindications to doxorubicin and dacarbazine
- Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
- Measurable disease on CT or MRI prior to randomization
- Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
- Consent to the proposed chemotherapy regimen
- Adequate bone marrow function: absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L
- Adequate liver function: bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
- Adequate cardiac function: satisfactory left ventricular systolic function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Doxorubicin
Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Other Names:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Other Names:
|
|
Experimental: Doxorubicin+Dacarbazine
Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Other Names:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Other Names:
Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1-year progression-free survival (PFS)
Time Frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS) |
Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
OS is defined as time from enrollment to death due to any cause |
Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
|
Objective Response Rate
Time Frame: After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
Proportion of patients achieving complete or partial response per RECIST 1.1 |
After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
|
incidence of Adverse events
Time Frame: During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Proportion of patients experiencing adverse events in each treatment arm |
During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Sarcoma
- Neoplasms, Connective and Soft Tissue
- Neoplasms, Muscle Tissue
- Leiomyosarcoma
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glycosides
- Triazenes
- Imidazoles
- Anthracyclines
- Naphthacenes
- Aminoglycosides
- Daunorubicin
- Doxorubicin
- Dacarbazine
Other Study ID Numbers
- 08202511001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.